AzTrials
AzTrials

Alzheimer s DiseaseNCT07402356

VR Pupillometry in Cognitive Impairment

An observational study of Alzheimer s Disease and Major Depressive Disorder (MDD), run by Max-Planck-Institute of Psychiatry at 1 site in Germany.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of… Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
How many people
140 participants
Where
1 siteGermany
Study dates
1 May 2025to 31 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Adults aged 18-80 years will be recruited at the Max Planck Institute of Psychiatry (Munich, Germany) from inpatient wards and outpatient clinics. Patients have a suspected or confirmed clinical diagnosis of Alzheimer's disease, mild cognitive impairment, or depressive disorder with cognitive impairment. Routine clinical measures (neuropsychological testing and, CSF biomarkers, blood biomarkers, imaging) will be linked to study pupillometry outcomes.

Who may be able to join

  • Written informed consent.
  • Age 18-80 years.
  • Ability to read and understand German.
  • For patient cohorts: suspected or confirmed diagnosis of AD/MCI/depressive disorder with cognitive impairment according to clinical assessment and routine documentation.

Who cannot join

  • Acute suicidality (e.g. BDI suicidality item > 1).
  • Change of psychotropic medication within the last 4 weeks.
  • Lifetime psychotic disorder (ICD-10 F20-29).
  • Lack of capacity to consent.
  • Lifetime bipolar disorder (ICD-10 F31).
  • Acute substance abuse or harmful use of alcohol or other psychoactive substances.
Show all 9Show fewer
  • Parkinson's syndrome (ICD-10 G20).
  • Multiple sclerosis (ICD-10 G35).
  • Stroke within the last 12 months.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Germany1 site, 1 recruiting
  • Max Planck Institute of Psychiatry

    München, Bavaria, 80804

    Eva Vidovic, MD, 089 30622 1402 ext. 0049, ambulanz@psych.mpg.de

    Victor I. Spoormaker, PhD, 089 30622 1402 ext. 0049, ambulanz@psych.mpg.de

    Recruiting

Other trials in Germany

About this study

Official title: Task-evoked Pupillometry in AD, MCI, and Depression-Related Cognitive Impairment

With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of cognitive impairment and its progression over time. Pupil responses are linked to brain arousal systems relevant to cognitive dysfunction, including the locus coeruleus, which is affected early in Alzheimer's disease. Adults aged 18-80 years will be assigned to one of four cohorts (n=35 per cohort): i) Alzheimer's disease (supported by CSF biomarkers), ii) mild cognitive impairment (MCI) without Alzheimer's Disease, iii) depressive disorder with cognitive impairment, iv) healthy controls. Participants will undergo initial assessments at baseline and follow-up visits after 3 and 6 months. At each visit, pupil responses and behavioral metrics are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Pupillometric and behavioral metrics will be compared across cohorts and related to routine neuropsychological measures (MoCA, CERAD) and available clinical biomarkers (CSF markers; blood biomarkers). The primary objective is to determine whether task-evoked pupil response profiles sensitively quantify cognitive impairment, differ between cohorts, and track change over time. The long-term goal is to validate an easy-to-use, outpatient-compatible assessment to support objective characterization and monitoring of cognitive disorders.

Read the detailed description

Cognitive performance typically declines with age and is usually accompanied by attention and memory deficits. While such changes can be consistent with normal ageing, they may also reflect affective disorders or early stages of neurodegenerative diseases (e.g. Alzheimer's Disease; AD). In clinical practice, neurocognitive tests are commonly used to distinguish age-appropriate change from pathological decline. As these tests quantify behavioral performance, they are better at detecting cognitive decline, once measurable deficits are manifested. However, they have limited sensitivity to subtle changes that can precede overt clinical symptoms by several years. This study evaluates a diagnostic approach based on pupil dilation measurements that may support earlier detection and longitudinal monitoring, potentially enabling earlier interventions.

Pupillometry provides a noninvasive index of pupil dynamics linked to arousal systems relevant to cognition, including the locus coeruleus-noradrenergic (LC-NA) system. LC-NA activity is coupled to pupil dilation via autonomic pathways, and this coupling has been demonstrated across animal and human studies. Given its widespread projections, the LC-NA system is implicated in psychiatric and neurological conditions through roles in arousal regulation, stress responsivity, attention, and memory. Pupillometry in Alzheimer's disease has often been examined using pupillary light reflex paradigms. However, simple light-flash measures may be less informative in early-stage impairment because pupil responses vary with cognitive state and task demands and do not provide a uniform, task-independent readout of LC-linked function. Accordingly, analyzing pupil responses during and immediately following cognitive tasks may be better suited to capturing subtle dysfunction relevant to prodromal processes, with light-reflex alterations potentially becoming more apparent once impairment is established. In prior work, the investigators observed pupil diameter increased with working-memory load during an N-back task. Most participants showed the expected increase in pupil dilation with task difficulty, whereas a subset exhibited pronounced atypical pupil responses despite only slight differences on standard neurocognitive measures. Building on these principles, this study uses a VR-based assessment to examine adults presenting with early, non-specific cognitive complaints. By systematically recording pupil dynamics during and following cognitive paradigms, the investigators aim to obtain readouts of LC-NA system function that may support differential diagnosis among conditions with overlapping clinical presentations (e.g. depression-related cognitive impairment vs. early dementia).

At each visit, participants are fitted with a VR headset by trained study personnel and complete VR-based assessments with concurrent eye tracking and behavioral performance recording. Assessments are conducted at baseline (T0) and repeated after 3 months (T1) and 6 months (T2). At each visit, pupil responses and task performance are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Participants also complete routine neuropsychological testing, including the Montreal Cognitive Assessment (MoCA) and the CERAD battery comprising semantic fluency, Boston Naming Test, Mini-Mental State Examination (MMSE), word list learning, word list delayed recall, word list recognition, figure copying, figure delayed recall, phonemic fluency, and Trail Making Test. Additional assessments include the Bayer Activities of Daily Living scale (Bayer-ADL) and the Geriatric Depression Scale (GDS), as well as questionnaires assessing subjective cognitive impairment (FLei) and childhood adversity (CTQ). Sociodemographic data are recorded, including age, sex, education (years of schooling), and occupation. Blood is collected for routine laboratory measures and blood-based biomarker analyses (including phosphorylated tau 217), and clinical data from routine care are linked where available. In some cases, cerebrospinal fluid biomarkers from routine clinical evaluation are available and linked, including AD pathology markers (amyloid-β and tau measures).

Pupillometric and behavioral measures will be compared across cohorts and evaluated longitudinally across follow-up visits. Measures will also be related to routine neuropsychological assessment, as well as available clinical biomarkers (CSF amyloid-β and tau measures blood-based biomarkers and anatomical neuroimaging sequences). Prior observations suggest that pupil dilation scales with cognitive load and that task-evoked pupil responses can differ, even when standard neurocognitive measures show only subtle differences. The investigators hypothesize that task-evoked pupil response patterns will differ between cohorts and may be sensitive to change over time.

Keywords
Alzheimer's Disease, Major Depressive Disorder, Mild Cognitive Impairment, Dementia, Pupillometry, Biomarkers, Amyloid beta-Peptides, Tau Proteins
Medical subject headings
Depressive Disorder, Major, Cognitive Dysfunction, Dementia, Alzheimer Disease, Plaque, Amyloid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07402356
Study groupRoleWhat they receive
Alzheimer's DiseaseParticipants with complaints of cognitive deficits and a diagnosis of Alzheimer's disease (AD) supported by cerebrospinal fluid (CSF) biomarker profile, where available.
Mild Cognitive Impairment without Alzheimer's DiseaseParticipants with complaints of cognitive deficits meeting criteria for mild cognitive impairment without evidence of Alzheimer's disease (CSF biomarkers not consistent with AD).
Depressive Disorder With Cognitive ImpairmentParticipants with complaints of cognitive impairment and no evidence of Alzheimer's pathology; deficits most consistent with depressive disorder.
Healthy ControlsAge-matched healthy volunteers.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Task-evoked pupil dilation during N-Back

    Pupil response metrics (mean relative pupil diameter in each condition) recorded with VR eye tracking during the N-back task for each condition (fixation, 0-back, 1-back, 2-back).

    Measured: Baseline

Secondary outcomes (12)
  1. Resting-state pupil dynamics

    Mean and variability of pupil diameter during resting fixation.

    Measured: Baseline, 3 months, 6 months.

  2. Reward-task pupil response

    Pupil response metrics (mean relative pupil diameter in each condition) recorded with VR eye tracking during each condition (reward, control).

    Measured: Baseline, 3 months, 6 months.

  3. N-back behavioral performance

    Behavioral performance during the VR N-back task, quantified as accuracy and reaction time for each load condition ( 0-, 1-, 2-back).

    Measured: Baseline, 3 months, 6 months.

  4. Montreal Cognitive Assessment (MoCA)

    Global cognitive screening tool used to quantify overall cognitive impairment. Range: 0-30; higher scores indicate better cognitive performance.

    Measured: Baseline, 3 months, 6 months.

  5. CERAD cognitive battery (CERAD-Plus), norm-referenced z-scores

    CERAD-Plus subtests include semantic fluency, Boston Naming Test, word list learning, word list delayed recall, word list recognition, figure copying, figure delayed recall, phonemic fluency, and Trail Making Test. The subtests will be evaluated using age-/education-adjusted norm-referenced z-scores. A z-score of 0 corresponds to the normative mean; higher z-scores indicate better cognitive performance and lower z-scores indicate worse performance.

    Measured: Baseline, 6 months.

  6. Bayer Activities of Daily Living (Bayer-ADL)

    Functional status measured using the Bayer-ADL mean item score (quotient). Range: 1.00-10.00. Higher scores indicate worse functional impairment (more difficulty with activities of daily living).

    Measured: Baseline, 6 months.

  7. Geriatric Depression Scale

    Geriatric Depression Scale, 30-item version (GDS-30), total score (depressive symptoms). Range: 0-30; higher scores indicate more depressive symptoms.

    Measured: Baseline, 6 months.

  8. Subjective cognitive impairment (Fragebogen zur geistigen Leistungsfähigkeit; FLei), total score

    35-item self-report assessing cognitive difficulties over the last 6 months (0-4 per item). Range: 0-140. Higher scores indicate greater subjective cognitive impairment (more perceived difficulties).

    Measured: Baseline, 6 months.

  9. Childhood Trauma Questionnaire (CTQ)

    Retrospective recall-based measures administered to adults. Used to determine experiences of childhood trauma. Higher scores indicate greater childhood adversity.

    Measured: Baseline.

  10. Blood-based biomarkers

    Blood biomarker concentrations assessed from collected blood samples, including phosphorylated tau 217 (p-tau217) and Aβ1-42/Aβ1-40 ratio.

    Measured: Baseline, 6 months.

  11. CSF Alzheimer's disease pathology markers

    CSF biomarkers from routine clinical evaluation where available, including Aβ1-42, Aβ1-40, Aβ1-42/Aβ1-40 ratio, total tau, and phosphorylated tau.

    Measured: Baseline.

  12. Task-evoked pupil dilation during N-Back

    Pupil response metrics (mean relative pupil diameter in each condition; load-dependent slope across conditions) recorded with VR eye tracking during the N-back task for each condition (fixation, 0-back, 1-back, 2-back).

    Measured: 3 months, 6 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Feb 2026
  2. Study start1 May 2025
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
140 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07402356
Sponsor's protocol ID
23-0991
Status last verified
Feb 2026
First submitted
12 Jan 2026
Last updated
17 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Murphy PR, O'Connell RG, O'Sullivan M, Robertson IH, Balsters JH. Pupil diameter covaries with BOLD activity in human locus coeruleus. Hum Brain Mapp. 2014 Aug;35(8):4140-54. doi: 10.1002/hbm.22466. Epub 2014 Feb 7.

    PubMed 24510607
  • Megemont M, McBurney-Lin J, Yang H. Pupil diameter is not an accurate real-time readout of locus coeruleus activity. Elife. 2022 Feb 2;11:e70510. doi: 10.7554/eLife.70510.

    PubMed 35107419
  • Fietz J, Pohlchen D; BeCOME Working Group; Bruckl TM, Brem AK, Padberg F, Czisch M, Samann PG, Spoormaker VI. Data-Driven Pupil Response Profiles as Transdiagnostic Readouts for the Detection of Neurocognitive Functioning in Affective and Anxiety Disorders. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Jun;9(6):580-587. doi: 10.1016/j.bpsc.2023.06.005. Epub 2023 Jun 20.

    PubMed 37348604
  • Fietz J, Pohlchen D, Binder FP; BeCOME Working Group; Czisch M, Samann PG, Spoormaker VI. Pupillometry tracks cognitive load and salience network activity in a working memory functional magnetic resonance imaging task. Hum Brain Mapp. 2022 Feb 1;43(2):665-680. doi: 10.1002/hbm.25678. Epub 2021 Oct 8.

    PubMed 34622518
  • Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:403-50. doi: 10.1146/annurev.neuro.28.061604.135709.

    PubMed 16022602

Questions about this trial

What is this clinical trial studying?

An observational study of Alzheimer s Disease and Major Depressive Disorder (MDD), run by Max-Planck-Institute of Psychiatry at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Eva Vidovic, MD (089-30622-1402 ext. 0049, eva_vidovic@psych.mpg.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Task-evoked pupil dilation during N-Back (time frame: Baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07402356, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in